Abstract
Immunotherapy is known to provide a substantial survival benefit to a select group of non-small cell lung cancer (NSCLC) patients, therefore, early identification of progression provides a more beneficial treatment to these patients. Serum tumor markers can be used to monitor the response to treatment, however no clear guidance is available how to use and interpret their longitudinal results. Our study aims to evaluate and compare longitudinal biomarker analysis methods, in early detection of progressive disease in immunotherapy treated NSCLC patients.
Original language | English |
---|---|
Article number | PCN279 |
Pages (from-to) | S472-S472 |
Journal | Value in health |
Volume | 23 |
Issue number | Suppl. 2 |
DOIs | |
Publication status | Published - Dec 2020 |
Keywords
- 22/4 OA procedure